적복령 추출물이 파골세포의 분화와 골흡수 억제에 미치는 효과
Inhibition of Osteoclast Differentiation and Bone Resorption by Poria cocos Wolf Extract
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives: Osteoclast differentiation and bone resorption are considered a potential therapeutic target to the treatment of erosive bone diseases, including osteoporosis and rheumatoid arthritis. Poria cocos Wolf (PCW), commonly used herbal medicine, has previously been reported to induce anti-inflammatory effect and anti-cancer effect, and to modulate immunologic responses. However, the effects of PCW on osteoclasts, and its detailed mechanisms are not proven. Therefore, we examined the inhibitory mechanism of PCW on osteoclast differentiation and bone resorption. Materials and Methods: To analyze the effects of PCW on osteoclast differentiation, we examined osteoclast differentiation in bone marrow macrophages (BMMs) treated with or without of PCW by TRAP staining. The expression of c-Fos, NFATc1, TRAP and OSCAR mRNA was determined by RT-PCR and the protein levels of c-Fos, NFATc1, p38, ERK, JNK, Akt and IκB were assessed by western blot. Also, we evaluated the effect of PCW on bone resorption using hydroxyapatite plate. Results: PCW significantly inhibited RANKL-mediated osteoclast differentiation without any evidence of cytotoxicity. We founded that PCW strongly inhibited RANKL-induced osteoclast formation when added during the early stage of cultures, suggesting that PCW acts on osteoclast precursors to inhibit RANKL/RANK signaling. Among the RANK signaling pathways, PCW inhibited the phosphorylation of p38 and JNK, also inhibited RANKL-induced expression of c-Fos, NFATc1, TRAP and OSCAR. In addition, PCW suppressed the bone resorption of mature osteoclasts. Conclusions: These findings suggest that PCW may be a potential novel drug for bone disorders by targeting the differentiation of osteoclasts as well as their functions.
Abstract
Objectives: Osteoclast differentiation and bone resorption are considered a potential therapeutic target to the treatment of erosive bone diseases, including osteoporosis and rheumatoid arthritis. Poria cocos Wolf (PCW), commonly used herbal medicine, has previously been reported to induce anti-inflammatory effect and anti-cancer effect, and to modulate immunologic responses. However, the effects of PCW on osteoclasts, and its detailed mechanisms are not proven. Therefore, we examined the inhibitory mechanism of PCW on osteoclast differentiation and bone resorption. Materials and Methods: To analyze the effects of PCW on osteoclast differentiation, we examined osteoclast differentiation in bone marrow macrophages (BMMs) treated with or without of PCW by TRAP staining. The expression of c-Fos, NFATc1, TRAP and OSCAR mRNA was determined by RT-PCR and the protein levels of c-Fos, NFATc1, p38, ERK, JNK, Akt and IκB were assessed by western blot. Also, we evaluated the effect of PCW on bone resorption using hydroxyapatite plate. Results: PCW significantly inhibited RANKL-mediated osteoclast differentiation without any evidence of cytotoxicity. We founded that PCW strongly inhibited RANKL-induced osteoclast formation when added during the early stage of cultures, suggesting that PCW acts on osteoclast precursors to inhibit RANKL/RANK signaling. Among the RANK signaling pathways, PCW inhibited the phosphorylation of p38 and JNK, also inhibited RANKL-induced expression of c-Fos, NFATc1, TRAP and OSCAR. In addition, PCW suppressed the bone resorption of mature osteoclasts. Conclusions: These findings suggest that PCW may be a potential novel drug for bone disorders by targeting the differentiation of osteoclasts as well as their functions.
참고문헌 (30)
- Kanis JA, "Diagnosis of osteoporosis and assessment of fracture risk", Lancet, 359, pp.1929~1936 (2002)
- The Korea Institute for Health and Social Affairs and the Korea Centers for Disease Control and Prevention, "The fourth Korea National Health and Nutrition Examination Survey (KNHANES)", ~ (2008)
- Kang HY, "Incidence and mortality of hip fracture among the elderly population in South Korea: a population-based study using the national health insurance claims data", BMC Public Health, 10, pp.230~ (2010)
- National Osteoporosis Foundation, "Clinician’s guide to prevent and treatment of osteoporosis", National Osteoporosis Foundation, ~ (2010)
- Cooper C, "Hip fractures in the elderly: a world-wide projection", Osteoporos Int, 2, pp.285~289 (1992)
- Canalis E, "Effect of growth factors on bone cell replication and differentiation", Clin Orthop Relat Res, 193, pp.246~263 (1985)
- Teti A, "Bone development: overview of bone cells and signaling", Curr Osteoporos Rep, 9, pp.264~273 (2011)
- Canalis E, "Growth factors and the regulation of bone remodeling", J Clin Invest, 81, pp.277~281 (1988)
- Boyle WJ, "Osteoclast differentiation and activation", Nature, 423, pp.337~342 (2003)
- Suda T, "Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families", Endocr Rev, 20, pp.345~357 (1999)
- Del Fattore A, "Osteoclast receptors and signaling", Arch Biochem Biophys, 473, pp.147~160 (2008)
- Lee ZH, "Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts", Biochem Biophys Res Commun, 305, pp.211~214 (2003)
- Takayanagi H, "The role of NFAT in osteoclast formation", Ann N Y Acad Sci, 1116, pp.227~237 (2007)
- Kim K, "Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activationinduced cytokine-mediated osteoclastogenesis", J Biol Chem, 280, pp.35209~35216 (2005)
- Takayanagi H, "Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts", Dev Cell, 3, pp.889~901 (2002)
- Kwak HB, "Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss", Biol Pharm Bull, 32, pp.1193~1198 (2009)
- Nishikawa M, "Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures", Bone, 18, pp.9~14 (1996)
- Solomon DH, "Osteoporosis treatments and adverse events", Curr Opin Rheumatol, 21, pp.363~368 (2009)
- Hong JS, "Composition of organic acid and fatty acid in Pleurotus ostreatus, Lentinus edodes and Agaricus bisporus", J Korean Soc Food Sci Nutr, 20, pp.100~105 (1988)
- Chihara G, "Carboxymethylpachmaran a new water soluble polysaccharide with marked antitumor activity", Nature, 233, pp.486~490 (1971)
- Kwon MS, "Quality and functional characteristics of cultivated Hoelen (Poria cocos Wolf) under the picking data", J Korean Soc Food Sci Nutr, 27, pp.1034~1040 (1998)
- Kanayama H, "A new antitumor polysaccharide from the mycelia of Poria cocos Wolf", Chem Pharm Bull, 31, pp.1115~1119 (1983)
- Nukaya H, "Isolation of inhibitors of TPA-induced mouse ear edema form Hoele, Poria cocos", Chem Pharm Bull, 44, pp.847~850 (1996)
- Nishikawa M, "Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures", Bone, 18, pp.9~14 (1996)
- Khosla S, "Bisphosphonateassociated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 22, pp.1479~1491 (2007)
- Wong BR, "The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor", J Biol Chem, 273, pp.28355~28359 (1998)
- Hsu H, "Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand", Proc Natl Acad Sci U S A, pp.3540~3545 (1999)
- Eferl R, "AP-1: a double-edged sword in tumorigenesis", Nat Rev Cancer, 3, pp.859~868 (2003)
- Wagner EF, "Fos", AP-1 proteins in bone and the immune system, 2005, pp.208, 126~140
- 천윤희, "파골세포 분화에 복령 추출물이 미치는 영향", 동의생리병리학회지, 26(3), pp.320~324 (2012), 대한동의병리학회[DOI]